SEPN
Septerna, Inc.
NASDAQ · USHealthcareBiotechnology
$32.21-3.56%
Price as of Jul 20, 2026
SEPN financials
Septerna, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $46.0M | $1.1M | $151.0K | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $46.0M | $1.1M | $151.0K | $0.00 |
| Operating expenses | $126.7M | $81.9M | -$1.9M | $28.0M |
| Operating income | -$80.8M | -$80.8M | $2.1M | -$28.0M |
| Net income | -$48.9M | -$71.8M | $4.2M | -$27.7M |
| EBITDA | -$47.3M | -$70.9M | -$44.7M | -$27.4M |
| Basic EPS | $-1.10 | $-1.93 | $0.03 | $-1.42 |
| Diluted EPS | $-1.10 | $-1.93 | $0.03 | $-1.42 |
| Balance sheet | ||||
| Cash & equivalents | $120.7M | $238.2M | $88.5M | $30.6M |
| Total assets | $596.2M | $456.6M | $130.9M | $36.1M |
| Total liabilities | $214.3M | $36.5M | $169.2M | $80.3M |
| Stockholders’ equity | $381.9M | $420.0M | -$38.4M | -$44.2M |
| Total debt | $23.6M | $25.5M | $12.6M | $710.0K |
| Net debt | -$97.1M | -$212.7M | -$75.9M | -$29.9M |
| Cash flow | ||||
| Operating cash flow | $110.2M | -$67.5M | -$38.7M | -$23.3M |
| Capital expenditure | -$518.0K | -$2.1M | -$2.9M | -$1.3M |
| Free cash flow | $109.7M | -$69.6M | -$41.6M | -$24.6M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | -$1.0K | -$1.0K | -$1.0K | $0.00 |